We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

Alzheimer's disease, a devastating neurodegenerative condition that impacts millions globally, may have found an unexpected ...

The next Alzheimer’s treatment could come from an unexpected place. In new research released this week, scientists have found ...

The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.

The FDA approves a new maintenance dosing regimen for lecanemab (Leqembi; Eisai) in patients with early-stage Alzheimer ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...

Jan. 21, 2025 — Antibiotics, antivirals, vaccinations and anti-inflammatory medication are ... significantly reduce disease markers associated with Alzheimer's, new research has found.

European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for ...

SaveHealth provides an overview of Alzheimer's disease, including treatment and coping mechanisms for those with the disease ...